Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses of $(3.86) per share from the same period last year. The company reported quarterly sales of $13.544 million which beat the analyst consensus estimate of $7.723 million by 75.38 percent. This is a 577.88 percent increase over sales of $1.998 million the same period last year.